NCI-MATCH Press Center
The materials posted in this section are a collection of press releases, announcements, news stories, and blogs about the NCI-MATCH trial. For media inquiries, send an email or call 215.789.3631.
Looking for a publication? Search and sort this NCI-MATCH Publications List.
June 15, 2023
Nature Medicine publishes key lessons from NCI-MATCH to guide future precision medicine trials. Media Advisory
May 8, 2023
NCI-MATCH named among five innovative oncology therapies changing the game. MDLinx
October 26, 2022
NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib in Arm Z1K. Press Release
August 16, 2022
NCI-MATCH precision medicine trial leads to FDA drug approval: Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600Emutation. Blog Post
June 22, 2022
FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH. OncLive
June 1, 2022
Precision medicine clinical trials: A conversation between Peter O’Dwyer and Lale Kostakoglu. The Journal of Nuclear Medicine
April 15, 2022
NCI-MATCH: The Blueprint for Future Precision Medicine Trials. In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee of the Developmental Therapeutics Committee is offering expertise moving forward. Blog Post
April 11, 2022
As NCI-MATCH winds down, the cancer research community takes stock of lessons learned. Precision Oncology News/GenomeWeb
March 17, 2022
NCI-MATCH umbrella trial adds arm for LAG-3 expressing, mismatch repair deficient cancers. Precision Oncology News/GenomeWeb
March 16, 2022
ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations. Press Release
July 14, 2021
Matchmakers: How Basket Trials Match Patients With Drugs Based on Their Tumors. Cure Today
June 24, 2021
For patients with advanced or rare cancers, NCI-MATCH may offer a treatment option. Blog Post
Advocacy and the NCI’s National Clinical Trials Network Blog Post
May 7, 2021
NCI-MATCH has 12 open arms awaiting patients with advanced or rare cancers, and is expanding with the opening of a new treatment arm. Blog Post
April 27, 2021
The search for patients intensifies with the opening of a new NCI-MATCH treatment arm. Blog Post
April 26, 2021
A new study arm opens in NCI-MATCH, expanding patients’ potential to qualify for this precision medicine cancer clinical trial when they may not have other options. Press Release
October 19, 2020
A genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks. Blog Post
October 16, 2020
Data from the NCI-MATCH precision medicine trial established a new benchmark for next-generation sequencing in clinical trials. The Cancer Letter
October 14, 2020
NCI-MATCH data shows the value of platform trials for patients with rare genomically driven cancers. Interview with lead investigator Keith T. Flaherty, MD. Precision Oncology News/GenomeWeb
October 13, 2020
NCI-MATCH precision medicine cancer trial makes a major contribution to tumor gene testing for cancer treatment selection. Journal of Clinical Oncology publishes molecular analysis of 6000 NCI-MATCH patients. Press Release
August 13, 2020
In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report on Arm H. The combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAF V600>-mutated tumors outside of currently approved indications. OncLive
February 20, 2020
The results of Arm Z1D in the NCI-MATCH trial continue to attract media attention. Nilofer Azad, MD (Johns Hopkins) talks about the activity of nivolumab in MMR-deficient cancers in a feature article. MedPage Today/ASCO Reading Room
January 13, 2020
A series of changes were recently incorporated in Addendum #24 of the NCI-MATCH trial. Blog Post
January 7, 2020
Komal Jhaveri, MD, FACP (Memorial Sloan Kettering) is the primary author of the publication of NCI-MATCH Arm Q results, published in the Annals of Oncology. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors. Press Release
December 19, 2019
The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH. “The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36%–or 15 of 42 patients with cancers other than colon,” says Nilofer Azad, MD (Johns Hopkins University). Press Release
June 3, 2019
Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations. “Arm H met its primary endpoint with an overall objective response rate of 33 percent,” said lead researcher April K. S. Salama, MD (Duke University). Press Release
November 12, 2018
NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly. Findings from Arm Y are to be presented at an international meeting. Press Release
June 4, 2018
NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, has achieved a milestone with the release of results of several treatment arms of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities. Press Release
May 30, 2018
NCI-MATCH (EAY131) achieves a milestone with the release of patient outcomes results from Arms I, Q, and W at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. Press Release
July 7, 2017
James Doroshow discusses how NCI-MATCH tests the ability to integrate next-generation sequencing. The Cancer Letter
July 7, 2017
NCI-MATCH keeps enrolling. Targeted mutations are proving to be less common than estimated. The Cancer Letter
June 7, 2017
As the NCI-MATCH precision medicine cancer trial reaches its 6,000-patient tumor sequencing goal two years early, the trial continues with a new strategy to complete enrollment by casting a wider net for patients. Press Release
September 26, 2016
ECOG-ACRIN opens the quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ today. COMET is an ancillary study to the NCI-MATCH (EAY131) trial, already underway. Press Release
August 16, 2016
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ to the NCI-MATCH (EAY131) trial, already underway. Press Release
May 26, 2016
The phase 2 precision medicine cancer trial, Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) is set to resume gene testing of patients on May 31, 2016, at 12:00 Noon Eastern Time. Press Release
September 4, 2015
The NCI-MATCH trial opens. The Cancer Letter
August 17, 2015
ECOG-ACRIN opens the phase 2 precision medicine cancer trial, National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131), the largest, most scientifically rigorous precision medicine trial in cancer to date, to cancer centers and community hospitals nationwide. Press Release
June 5, 2015
NCI-MATCH to bring in public, and private funds, giving NCI a new urgent scientific agenda. The Cancer Letter
June 5, 2015
Jim Doroshow on how NCI-MATCH is an example of what smart public-private partnerships can do. The Cancer Letter
June 1, 2015
National Cancer Institute and ECOG-ACRIN announce the NCI-MATCH / EAY131 trial, a multi-arm phase 2 precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancer type. Press Release
